Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis

Documenti analoghi

• Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
  di: A. O. Bobkova, et al.
  Pubblicazione: (2024-08-01)
• The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
  di: A. E. Karateev, et al.
  Pubblicazione: (2022-05-01)
• The association between genetic characteristics and treatment failure when switching from biologic disease-modifying antirheumatic drugs/Janus kinase inhibitors in patients with rheumatoid arthritis
  di: A. O. Bobkova, et al.
  Pubblicazione: (2025-02-01)
• Dynamics of global longitudinal strain of the left ventricular myocardium and blood biomarker levels in patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors
  di: Yu. N. Gorbunova, et al.
  Pubblicazione: (2023-10-01)
• Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
  di: A. E. Karateev, et al.
  Pubblicazione: (2022-09-01)